The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management (Q38796753)

6 September 2017

The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management (English)

1 reference

Radboud J Duintjer Tebbens

6 September 2017

1 reference

series ordinal

1

object named as

Radboud J Duintjer Tebbens

1 reference

6 September 2017

2

Kimberly M Thompson

1 reference

6 September 2017

10 November 2016

1 reference

6 September 2017

13

1 reference

based on heuristic

inferred from page(s)

published in

Future Microbiology

1 reference

6 September 2017

11

1 reference

6 September 2017

1549-1561

1 reference

Intrafamilial and interfamilial spread of living vaccine strains of polioviruses

6 September 2017

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Expert review on poliovirus immunity and transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Seroprevalence of antibody against poliovirus in inner-city preschool children. Implications for vaccination policy in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Live, orally given poliovirus vaccine. Effects of rapid mass immunization on population under conditions of massive enteric infection with other viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Vaccine policy changes and epidemiology of poliomyelitis in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Vaccine-derived polioviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Poliovirus excretion among persons with primary immune deficiency disorders: summary of a seven-country study series

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

A large vaccine-derived poliovirus outbreak on Madura Island--Indonesia, 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Preeradication vaccine policy options for poliovirus infection and disease control.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

New strategies for the elimination of polio from India

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

An economic analysis of poliovirus risk management policy options for 2013-2052

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Polio vaccination: past, present and future.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Affordable inactivated poliovirus vaccine: strategies and progress

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Modeling options to manage type 1 wild poliovirus imported into Israel in 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Polio endgame: the global switch from tOPV to bOPV.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

An Introduction to Poliovirus: Pathogenesis, Vaccination, and the Endgame for Global Eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Polio endgame: the global introduction of inactivated polio vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

The new polio eradication end game: rationale and supporting evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

The final stages of the global eradication of poliomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Poliovirus vaccination options for achieving eradication and securing the endgame

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Achieving and maintaining polio eradication--new strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Modeling the dynamics of oral poliovirus vaccine cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Combinations of Quality and Frequency of Immunization Activities to Stop and Prevent Poliovirus Transmission in the High-Risk Area of Northwest Nigeria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Polio eradication. Efficacy of inactivated poliovirus vaccine in India

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

21 January 2018

Future of polio vaccines

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Rationalizing the development of live attenuated virus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Cold-Adapted Viral Attenuation (CAVA): Highly Temperature Sensitive Polioviruses as Novel Vaccine Strains for a Next Generation Inactivated Poliovirus Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

New Strains Intended for the Production of Inactivated Polio Vaccine at Low-Containment After Eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

The costs of future polio risk management policies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

The potential impact of expanding target age groups for polio immunization campaigns

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Establishing a Global Vaccine-Development Fund

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

A global call for new polio vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0126

21 January 2018

Identifiers

DOI

10.2217/FMB-2016-0126

1 reference

6 September 2017

1 reference

PubMed ID

27831742